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Late loss of allograft function is primarily attributed
to chronic rejection (CR). There are no effective treat-
ments for CR and the underlying cause of the disease is
unknown. This study compared events that occurred
within cardiac allografts placed in mice that received
either anti-CD4 therapy and develop CR or anti-CD40L
therapy and do not develop CR. Both TGFb and connec-
tive tissue growth factor (CTGF), which is induced by
TGFb , were expressed in grafts with CR but were not
expressed in grafts without CR. TGFb transfection of
allografts in anti-CD40L-treated recipients resulted in
CTGF expression and CR. However, TGFb transfection
of syngeneic grafts did not result in CTGF expression
or CR. These data indicate that TGFb alone is insuffi-
cient to induce CR and that CTGF is required. Further,
antigenic stimulation is required for TGFb induction of
CTGF. Thus, CTGF may serve as a therapeutic target
for CR.
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Introduction
Chronic rejection (CR) is the leading cause of late allo-
graft loss, and is prevalent in cardiac, lung, renal and to
†This manuscript is dedicated to Dr. Charley Orosz, who passed
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‡KC and SCW contributed equally to this study.
a lesser degree, liver transplantation (reviewed in 1). CR is
a progressive, irreversible disease that is characterized by
deteriorating graft function, interstitial fibrosis and the
occlusion of lumenal structures such as arteries and
epithelial-lined conduits (reviewed in 2–4). In cardiac and
renal allografts, subendothelial tissue develops in arter-
ies forming an occlusive neointima, which is referred to
as transplant-associated vasculopathy (TAV). Hence, TAV
and interstitial fibrosis are commonly viewed as surrogate
markers for CR. These pathologic changes of CR are dis-
tinct from those observed during acute rejection, where
inflammatory cell infiltration is associated with parenchy-
mal cell death. Rather, these changes resemble chronic
tissue remodeling and/or wound repair processes that fol-
low tissue injury (3). Despite intense investigation, the
etiology of CR and associated pathologies are very poorly
understood. While both alloantigen-dependent (i.e. MHC
disparity, No. of acute rejection episodes) and -independent
(i.e. ischemia/reperfusion injury) factors contribute to the
disease process (reviewed in 5,6), reliable therapeutic tar-
gets for prevention and treatment of CR have not been
identified. As summed up by Tilney and colleagues (5), ‘No
tests can predict the development of the process and no
drugs can control or reverse it’.
TGFb has been implicated in a number of fibrotic diseases
(7–10) including CR (11). TGFb also has numerous immuno-
suppressive activities that are viewed as beneficial in the
settings of inflammation and transplantation (reviewed in
12). Further, TGFb acts as a tumor suppressor for several
cell types, and interference with TGFb receptor signaling
may lead to cancer of epithelial cell origin (13). Hence, long-
term inhibition of TGFb as a treatment for CR could have
detrimental consequences.
CTGF is an immediate early response gene product that
is induced by TGFb (reviewed in 14,15). TGFb, but not
PDGF, FGF or EGF, has been shown to induce CTGF pro-
duction from a variety of cell types, utilizing a unique TGFb
response element that is not associated with other TGFb-
regulated promoters (16). CTGF mediates many of the
fibrogenic activities of TGFb, but not its antimitogenic ac-
tivity on epithelial cells (8,14,17). CTGF is mitogenic for fi-
broblasts and induces the production of collagen and other
extracellular matrix proteins from fibroblasts and mesan-
gial cells. While CTGF has been implicated in a variety of
fibrotic diseases (18–27), CTGF has received little attention
in the setting of transplantation. Hence, the current study
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investigated the relationship between TGFb-induced CTGF
and CR. Our observations suggest that CTGF may pro-
vide a target for preventing CR while sparing the anti-
inflammatory and anti-proliferative activities of TGFb.
Materials and Methods
Mice
Female C57BL/6 (H-2b) mice and BALB/c (H-2d) mice were purchased
from The Jackson Laboratories (Bar Harbor, ME) and housed under spe-
cific pathogen-free conditions in the Unit for Laboratory Animal Medicine at
the University of Michigan. Mice were used between 6–12 weeks of age.
Heterotopic cardiac transplantation
C57BL/6 mice were transplanted with intact BALB/c cardiac allografts,
as described (28). In this model, the donor heart is anastomosed to the
great vessels of the abdomen, perfused with recipient mouse’s blood
and resumes contraction. Transplant function was monitored by abdominal
palpation.
Assessment of chronic rejection
Functioning allografts were recovered at the indicated times post-
transplantation, fixed in formalin and embedded in paraffin. Sections were
stained with H&E to assess myocyte viability (i.e. presence of nuclei and
cross striation). As described (29), trichrome and elastin stains were used to
identify collagen deposition and the presence of neointima, respectively.
Anti-CD4 and anti-CD40L therapies to prolong allograft survival
Anti-CD4 (hybridoma GK1.5, obtained from American Type Culture Collec-
tion, Manassas, VA) and anti-CD40L (hybridoma MR1, kindly provided by
Dr. Randy Noelle, Dartmouth) mAb were purified and resuspended in PBS
by Ligocyte Pharmaceuticals (Bozeman, MT). To transiently deplete CD4+
cells, allograft recipients were injected i.p. with 1 mg of anti-CD4 mAb on
Figure 1. TGFb and CTGF expres-
sion segregate with CR. C57BL/6 mice
were transplanted with BALB/c cardiac
allografts and were given inductive anti-
CD4 or anti-CD40L therapy. Function-
ing allografts were recovered on day 60
post-transplant. Panel A represents a
histologic assessment of CR. V = oc-
cluded vessel, EM = elastic membrane.
Panel B depicts RT-PCR on RNA sam-
ples from 4 individual transplants per
group. For mTGFb, data are representa-
tive of 10 of 10 transplants for the anti-
CD4 group and 15 of 17 (2 were weakly
positive) for the anti-CD40L group. For
CTGF, data are representative of 14
of 17 (3 were negative) transplants
for the anti-CD4 group and 17 of 20
(3 were weakly positive) for the anti-
CD40L group.
days –1, 0 and 7 relative to transplantation (29–31). CD4+ cells begin to
repopulate the periphery between 3 and 4 weeks post-transplant. For in-
ductive anti-CD40L therapy, allograft recipients were injected i.p. with 1 mg
of anti-CD40L on days 0, 1 and 2 relative to transplantation (31,32).
Adenoviral-mediated transfection of cardiac allografts
As described (33,34), cardiac allografts were transfected by perfusion via
the aorta with E1/E3 deleted adenoviral vectors (5 × 108 pfu) encoding the
active form of human TGFb1 (Ad-TGFb) or beta-galactosidase (Ad-bgal). Fol-
lowing perfusion, donor grafts were recovered and placed in iced Ringer’s
for approximately 1 h prior to transplantation. Reporter gene studies with
Ad-bgal have revealed that the distribution of transgene expression within
the cardiac graft is patchy, and that both cardiac myocytes and cells of the
vasculature express the transgene product (33).
RNA isolation and RT-PCR
Cardiac allografts were homogenized in 1 ml TRIzol® (Invitrogen Life Tech-
nologies, Carlsbad, CA) and RNA was isolated as per manufacturer’s proto-
col. Two lg of total RNA were reverse transcribed using a cDNA Cycle® Kit
(Invitrogen Life Technologies) using oligo dT primers and AMV reverse tran-
scriptase to generate cDNA. Human TGFb1 (hTGFb) primers are specific for
hTGFb and do not amplify mouse TGFb (mTGFb) (34). Primer sequences:
hTGFb sense 5’ GTGGAAACCCACAACGAA 3’, anti-sense 5’ GGCGGCCG-
GTAGTGAAC 3’; mTGFb sense 5’ TGGCTTCTAGTGCTGACG 3’, anti-sense
5’ GTTGCTCCACACTTGAT 3’; CTGF sense 5’ ATCCCTGCGACCCACACAAG
3’, anti-sense 5’ CAACTGCTTTGGAAGGACTCGC 3’; c actin sense 5’ CCA-
CACAGAGTACTTGCGCTCAGG 3’, anti-sense 5’ CACCCTGTGCTGCTCAC-
CGAGGCC 3’. Samples were amplified using AmpliTaq DNA polymerase
(Perkin Elmer, Norwalk, CT) in a GeneAmp® PCR System 9700 (Applied
Biosystems Inc, Foster City, CA).
Quantitative RT-PCR
CTGF primers are listed above. Collagen (pro-collagen 1a) sense 5’
TCCCTACTCAGCCGTCTGTGCC 3’, anti-sense 5’ AGCCCTCGCTTCCG-
TACTCG 3’; GAPDH sense 5’ CTGGTGCTGAGTATGTCGTG 3’, anti-sense 5’
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CAGTCTTCTGAGTGGCAGTG 3’. Real-time PCR was performed on cDNA
using a Cepheid Smart Cycler c© System (Cepheid, Sunnyvale, CA) and
primer binding to DNA was detected by SYBER Green ITM dye (Roche,
Indianapolis, IN). Relative expression of CTGF and collagen is expressed as
the exponent of the base 2 of the difference between the cycle threshold of
CTGF or collagen versus GAPDH in transplant cDNA samples. Significance
was determined with an unpaired t-test with Welch’s correction.
Immunohistochemistry for CTGF
Allografts were paraffin embedded, sectioned, de-paraffinized and pro-
cessed for antigen retrieval in citrate buffer (Biocare Medical, Concord,
CA). Endogenous peroxidase was blocked using 0.3% H2O2/0.1% NaN3
in dPBS for 10 min prior to standard immunohistochemistry using affinity-
purified rabbit anti-CTGF (35). Biotinylated goat anti-rabbit secondary Ab
(1:150, BioSource International, Camarillo, CA) was added for 30 min, fol-
lowed by incubation with a 1:500 dilution of SA-HRP (BioSource) in PBS
for 30 min. Sections were developed with AEC (Moss, Pasadena, CA)
and counterstained with Harris hematoxylin (Fischer Scientific, Hampton,
NH).
Results and Discussion
Development of CR following inductive anti-CD4 vs.
anti-CD40L therapy
We have previously reported that inductive therapy with ei-
ther anti-CD4 (30,31) or anti-CD40L (31,32) mAb markedly
prolongs cardiac allograft survival. However, at 60 days
post-transplant functioning allografts in anti-CD4-treated
recipients develop TAV and exhibit interstitial collagen de-
position (29), while allografts in anti-CD40L-treated recipi-
ents do not (32) (Figure 1A).
Expression of TGFß and CTGF is associated with CR
Since TGFb has been associated with CR (reviewed in 11),
we assessed intragraft expression of TGFb on day 60 post-
transplant (Figure 1B). TGFb mRNA was readily detectable
in the allografts of anti-CD4-treated mice but was absent
in the anti-CD40L- treated group. This pattern of TGFb ex-
pression was observed in at least 10 individual transplants
per group. Since CTGF is induced by TGFb (16) and is re-
ported to mediate the fibrotic activity of TGFb (8,14), we
assessed CTGF expression in long-term allografts (Figure
1B). CTGF expression paralleled that of TGFb in at least 10
individual transplants per group. Thus, expression of TGFb
and CTGF segregated with the development of CR.
Allograft transfection with TGFß results in CTGF
expression and CR in anti-CD40L-treated recipients
To further explore the relationship between TGFb-induced
CTGF and CR, we transfected allografts with the active
form of hTGFb1 or bgal and transplanted them into recip-
ients that were treated with anti-CD40L mAb. Forced ex-
pression of active hTGFb, but not bgal, induced intragraft
expression of CTGF (Figure 2A) and resulted in the devel-
opment of CR (Figure 2B) in anti-CD40L-treated recipients.
This pattern of hTGFb and CTGF expression, and CR was
observed in at least 20 transplants per group.
Since TGFb induces CTGF in a variety of cell types (16),
we employed immunohistochemistry to localize CTGF in
hTGFb-transfected allografts (Figure 2C). CTGF protein
was readily identified in vascular endothelial cells and cells-
infiltrating vessels with TAV in hTGFb-transfected allo-
grafts, but not in uninvolved vessels in bgal-transfected
grafts.
The studies above were performed between days 50
and 60 post-transplantation. We have also assessed
TGFb-induced CTGF expression at earlier time points fol-
lowing transplantation of Ad-TGFb-transfected allografts
into anti-CD40L-treated recipients. Intragraft expression
of CTGF was readily detectable as early as day 7 post-
transplantation of hTGFb-transfected allografts. Further, fi-
brosis and TAV were evident by day 30 in these hTGFb-
transfected allografts (data not shown).
TGFß transfection does not induce CTGF expression
and CR in syngeneic cardiac grafts
It is well established that syngeneic grafts do not develop
CR rejection to the extent that allografts do (1,5), thereby
supporting a critical role for the immune system in the pro-
gression of CR. What is less clear is what role the immune
system might play in TGFb induction of CTGF and the sub-
sequent development of CR. To this end, we assessed the
impact of intragraft expression of active hTGFb and CTGF
induction in syngeneic grafts. As expected, transgene
expression was readily detected in Ad-TGFb-transfected
syngeneic grafts (Figure 3A). However, CTGF was ei-
ther weakly expressed or was not detectable in these
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Figure 2. Forced expression of TGFb induces CTGF and CR
anti-CD40L-treated allograft recipients. BALB/c allografts were
transfected with Ad-TGFb or Ad-bgal and transplanted into anti-
CD40L-treated C57BL/6 recipients. Functioning allografts were re-
covered between days 50 and 60 post-transplant. Panel A depicts
RT-PCR for the hTGFb transgene-induced CTGF, while Panel B
depicts the histologic assessment of CR (200X). Data in Panels
A and B are representative of >20 individual transplants for each
group. Panel C depicts immunohistochemical localization of CTGF
in TGFb-transfected allografts and the data are representative of
12 individual transplants for the Ad-TGFb group and 6 transplants
for the Ad-bgal group.
TGFb-transfected syngeneic grafts. To validate differences
in the levels of CTGF expression in TGFb-transfected syn-
geneic and allogeneic transplants, we performed real-time
PCR for CTGF in these grafts (Figure 3B, left panel). Signif-
icantly less CTGF was expressed in TGFb-transfected syn-
geneic transplants relative to their allogeneic counterparts.
We also assessed the level of collagen type I expression
in these tissues, since CTGF is known to induce collagen
production (8,14) and collagen deposition is a hallmark of
CR (2,3). As was the case with CTGF expression, collagen
expression was significantly reduced in TGFb-transfected
syngeneic grafts when compared to allografts (Figure 3B,
right panel). Importantly, the failure of active TGFb ex-
pression to induce CTGF and subsequent collagen expres-
sion correlated with the absence of histologically defined
CR in syngeneic grafts (Figure 3C). It is possible that the
hTGFb transgene is expressed at lower levels in syngeneic
grafts when compared to allografts, thereby resulting in
less CTFG and collagen expression. The primers we use to
specifically amplify hTGFb were designed for standard RT-
PCR and are not suited for quantitative RT-PCR. Hence, we
were unable to quantitatively compare expression levels of
the hTGFb transgene in syngeneic and allogeneic grafts.
However, it should be noted that equally intense bands
for hTGFb were observed in Figure 2A for allografts and
Figure 3A for syngeneic grafts as determined by standard
RT-PCR. Further, we have reported that similar levels of
bgal are expressed in Ad-bgal-transfected syngeneic and
allogeneic grafts as visually determined by X-gal staining
(33). Hence, we believe that the differences in CTGF and
collagen expression in Ad-TGFb-transfected syngeneic and
allogeneic grafts are not likely due to differential expression
of the hTGFb transgene.
While TGFb has been implicated in CR (11), the mecha-
nism by which this pleiotropic cytokine contributes to the
disease process has not been defined. This study reveals
a strict correlation between TGFb-induced CTGF and the
development of CR. Indeed, the expression of active TGFb
in the absence of CTGF was not sufficient to drive CR
(Figure 3). This is in keeping with the observation of Mori
et al. (36), who reported that both TGFb and CTGF were
required to induce chronic fibrosis when injected subcu-
taneously. While TGFb is the principal inducer of CTGF
(8,14,15), thrombin (37,38) and hypoxia (39) have also been
shown to induce CTGF. It is conceivable that allografts may
be exposed to thrombin and hypoxia, which may lead to fur-
ther CTGF production. It should be noted that TNFa (40),
IL-4 (41), and prostaglandins and prostacyclins (42,43) an-
tagonize CTGF. Hence, CTGF may be therapeutically inhib-
ited for the treatment of fibrotic diseases (44), including
CR. This approach would spare the anti-inflammatory ac-
tivities of TGFb, which are believed to be beneficial in the
context of transplantation.
The observations that TGFb-transfected syngeneic grafts
failed to express CTGF and develop CR (Figure 3) suggest
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Figure 2. Continued.
that a component of the immune system is necessary to
drive CTGF production in this system. It should be noted
that human c d, but not ab T cells have been shown to
produce CTGF in response to TGFb and IL-15 (45). In addi-
tion, NK cells, which may respond to MHC disparate allo-
grafts, have recently been shown to play a role in CR (46).
Further, TGFb-transfected allografts, but not syngeneic
grafts, were infiltrated by mononuclear cells (Figures 2B
vs. 3C), and these graft-infiltrating cells expressed CTGF
(Figure 2C). The contribution of the immune response to
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Figure 3. TGFb transfection
of syngeneic grafts does not
induce CTGF or CR. C57BL/6






recipients served as positive
controls. Functioning grafts
were recovered between days
50 and 60 post-transplant.
Panel A depicts RT-PCR
results for 5 TGFb-transfected
syngeneic grafts. Note weak
CTGF bands detected in 2
syngeneic grafts relative to
the allograft control. Panel B
depicts real-time RT-PCR data
for CTGF (left panel) and colla-
gen (right panel) in 5 individual
transplants per group. Panel C
depicts the absence of CR in
TGFb-transfected syngeneic
grafts.
CR is well established (1,5). This study provides insight as
to how elements of the immune response may do so.
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1. Häyry P, Isoniemi H, Yilmaz S et al. Chronic allograft rejection.
Immunol Rev 1993; 134: 33–81.
2. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387–
397.
3. Orosz CG, Pelletier RP. Chronic remodeling pathology in grafts.
Curr Opin Immunol 1997; 9(5): 676–680.
4. Weis M, von Scheidt W. Cardiac allograft vasculopathy: A review.
Circulation 1997; 96: 2069–2077.
5. Waaga AM, Gasser M, Laskowski I, Tilney NL. Mechanisms of
chronic rejection. Curr Opin Immunol 2000; 12: 517–521.
6. Tullius SG, Tilney NL. Both alloantigen-dependent
and -independent factors influence chronic allograft rejection.
Transplantation 1995; 59: 313–318.
7. Border WA, Ruoslahti E. Transforming growth factor-beta in dis-
ease: The dark side of tissue repair. J Clin Invest 1992; 90: 1–
7.
964 American Journal of Transplantation 2006; 6: 959–966





































































8. Franklin TJ. Therapeutic approaches to organ fibrosis. Int J
Biochem Cell Biol 1997; 29: 79–89.
9. Wahl SM. Transforming growth factor b: The good, the bad, and
the ugly. J Exp Med 1994; 180: 1587–1590.
10. Tabibzadeh S. Homeostasis of extracellular matrix by TGF-b and
lefty. Front Biosci 2002; 7: d1231–1246.
11. Jain S, Furness PN, Nicholson ML. The role of transforming
growth factor beta in chronic renal allograft nephropathy. Trans-
plantation 2000; 69: 1759–1766.
12. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-
beta. Annu Rev Immunol 1998; 16: 137–161.
13. Brattain MG, Markowitz SD, Willson JK. The type II transform-
ing growth factor-beta receptor as a tumor-suppressor gene. Curr
Opin Oncol 1996; 8: 49–53.
14. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue
growth factor: Potential role in glomerulosclerosis and tubuloint-
erstitial fibrosis. Kidney Int 2000; 58: 1389–1399.
15. Leask A, Abraham DJ. The role of connective tissue growth fac-
tor, a multifunctional matricellular protein, in fibroblast biology.
Biochem Cell Biol 2003; 81: 355–363.
16. Grotendorst GR, Okochi H, Hayashi N. A novel transforming
growth factor beta response element controls the expression
American Journal of Transplantation 2006; 6: 959–966 965
Csencsits et al.
of the connective tissue growth factor gene. Cell Growth Differ
1996; 7: 469–480.
17. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR.
Stimulation of fibroblast cell growth, matrix production, and gran-
ulation tissue formation by connective tissue growth factor. J In-
vest Dermatol 1996; 107: 404–411.
18. Igarashi A, Nashiro K, Kikuchi K et al. Connective tissue growth
factor gene expression in tissue sections from localized sclero-
derma, keloid, and other fibrotic skin disorders. J Invest Dermatol
1996; 106: 729–733.
19. Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S.
Connective tissue growth factor: A novel regulator of mucosal
repair and fibrosis in inflammatory bowel disease? Int J Biochem
Cell Biol 1998; 30: 909–922.
20. di Mola FF, Friess H, Martignoni ME et al. Connective tissue
growth factor is a regulator for fibrosis in human chronic pan-
creatitis. Ann Surg 1999; 230: 63–71.
21. Shi-wen X, Pennington D, Holmes A et al. Autocrine overexpres-
sion of CTGF maintains fibrosis: RDA analysis of fibrosis genes in
systemic sclerosis. Exp Cell Res 2000; 259: 213–224.
22. Paradis V, Dargere D, Vidaud M et al. Expression of connective
tissue growth factor in experimental rat and human liver fibrosis.
Hepatology 1999; 30: 968–976.
23. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF
expression is induced by TGF- beta in cardiac fibroblasts and car-
diac myocytes: A potential role in heart fibrosis. J Mol Cell Cardiol
2000; 32: 1805–1819.
24. Uzel MI, Kantarci A, Hong HH et al. Connective tissue growth
factor in drug-induced gingival overgrowth. J Periodontol 2001;
72: 921–931.
25. Wang S, Denichilo M, Brubaker C, Hirschberg R. Connective tis-
sue growth factor in tubulointerstitial injury of diabetic nephropa-
thy. Kidney Int 2001; 60: 96–105.
26. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor:
A new and important player in the pathogenesis of fibrosis. Curr
Rheumatol Rep 2002; 4: 136–142.
27. Razzaque MS, Foster CS, Ahmed AR. Role of connective tissue
growth factor in the pathogenesis of conjunctival scarring in ocular
cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2003; 44: 1998–
2003.
28. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of
hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in
rejection. Transplantation 1973; 16: 343–350.
29. Piccotti JR, Li K, Chan SY, Eichwald EJ, Bishop DK. Cytokine regu-
lation of chronic cardiac allograft rejection: Evidence against a role
for Th1 in the disease process. Transplantation 1999; 67: 1548–
1555.
30. Bishop DK, Shelby J, Eichwald EJ. Mobilization of T lymphocytes
following cardiac transplantation: Evidence that CD4-positive cells
are required for cytotoxic T lymphocyte activation, inflammatory
endothelial development, graft infiltration, and acute allograft re-
jection. Transplantation 1992; 53: 849–857.
31. Bishop DK, Chan Wood S, Eichwald EJ, Orosz CG. Immunobiology
of allograft rejection in the absence of IFN-gamma: CD8+ effector
cells develop independently of CD4+ cells and CD40-CD40 ligand
interactions. J Immunol 2001; 166: 3248–3255.
32. Nathan MJ, Yin D, Eichwald EJ, Bishop DK. The immunobiology of
inductive anti-CD40L therapy in transplantation: Allograft accep-
tance is not dependent upon the deletion of graft-reactive T cells.
Am J Transplant 2002; 2: 323–332.
33. Chan SY, Li K, Piccotti JR et al. Tissue-specific consequences
of the anti-adenoviral immune response: Implications for cardiac
transplants. Nat Med 1999; 5: 1143–1149.
34. Chan SY, Goodman RE, Szmuszkovicz JR, Roessler B, Eichwald
EJ, Bishop DK. DNA-liposome versus adenoviral mediated gene
transfer of transforming growth factor beta1 in vascularized car-
diac allografts: Differential sensitivity of CD4+ and CD8+ T cells
to transforming growth factor beta1. Transplantation 2000; 70:
1292–1301.
35. Steffen CL, Ball-Mirth DK, Harding PA, Bhattacharyya N, Pillai
S, Brigstock DR. Characterization of cell-associated and soluble
forms of connective tissue growth factor (CTGF) produced by fi-
broblast cells in vitro. Growth Factors 1998; 15: 199–213.
36. Mori T, Kawara S, Shinozaki M et al. Role and interaction of con-
nective tissue growth factor with transforming growth factor-beta
in persistent fibrosis: A mouse fibrosis model. J Cell Physiol 1999;
181: 153–159.
37. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent
GJ. Thrombin is a potent inducer of connective tissue growth
factor production via proteolytic activation of protease-activated
receptor-1. J Biol Chem 2000; 275: 35584–35591.
38. Howell DC, Goldsack NR, Marshall RP et al. Direct thrombin inhi-
bition reduces lung collagen, accumulation, and connective tissue
growth factor mRNA levels in bleomycin-induced pulmonary fibro-
sis. Am J Pathol 2001; 159: 1383–1395.
39. Kondo S, Kubota S, Shimo T et al. Connective tissue growth factor
increased by hypoxia may initiate angiogenesis in collaboration
with matrix metalloproteinases. Carcinogenesis 2002; 23: 769–
776.
40. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor
necrosis factor alpha suppresses the induction of connective tis-
sue growth factor by transforming growth factor-b in normal and
scleroderma fibroblasts. J Biol Chem 2000; 275: 15220–15225.
41. Rishikof DC, Ricupero DA, Kuang PP, Liu H, Goldstein RH.
Interleukin-4 regulates connective tissue growth factor expres-
sion in human lung fibroblasts. J Cell Biochem 2002; 85: 496–504.
42. Ricupero DA, Rishikof DC, Kuang PP, Poliks CF, Goldstein RH.
Regulation of connective tissue growth factor expression by
prostaglandin E2. Am J Physiol 1999; 277: L1165–1171.
43. Stratton R, Shiwen X, Martini G et al. Iloprost suppresses connec-
tive tissue growth factor production in fibroblasts and in the skin
of scleroderma patients. J Clin Invest 2001; 108: 241–250.
44. Blom IE, Goldschmeding R, Leask A. Gene regulation of connec-
tive tissue growth factor: New targets for antifibrotic therapy?
Matrix Biol 2002; 21: 473–482.
45. Workalemahu G, Foerster M, Kroegel C, Braun RK. Human c /d-
T lymphocytes express and synthesize connective tissue growth
factor: Effect of IL-15 and TGF-b 1 and comparison with a/b-T
lymphocytes. J Immunol 2003; 170: 153–157.
46. Uehara S, Chase CM, Kitchens WH et al. NK cells can trigger
allograft vasculopathy: The role of hybrid resistance in solid organ
allografts. J Immunol 2005; 175: 3424–3430.
966 American Journal of Transplantation 2006; 6: 959–966
